Lab-on-a-Chip Platform CellTrap Reveals How Single Immune Cells Attack Brain Tumors in Real Time
核心洞察
The CellTrap microfluidic platform enables real-time observation of individual immune cell–cancer cell interactions for up to 14 hours using standard fluorescence microscopy.
Initial experiments with glioblastoma (搜索) cells show that multiple immune cells attacking a single cancer cell leads to more frequent and intense tumor cell killing.
Early activation signals in immune cells were found to predict later cell-damaging effects, enabling the first direct link between early reactions and outcomes within the same cell-cell interaction.
A new microfluidic platform developed at the Technical University of Munich (搜索) (TUM) is providing an unprecedented window into the cellular battlefield of cancer immunotherapy. Dubbed CellTrap, the technology allows researchers to observe, for the first time, how individual immune cells engage with and kill cancer cells in real time—revealing that early activation signals can predict later tumor cell destruction.
The platform addresses a fundamental limitation of established laboratory assays, which typically capture only average values across large cell populations—such as how many cancer cells survive after immune cell exposure. What happens at the single-cell level, including the precise timing of contact, activation, and killing, has remained largely hidden.
How CellTrap Works
CellTrap consists of a microfluidic chip featuring a large main channel that branches out continuously into 1,024 small trapping chambers. Individual immune cells and cancer cells are selectively drawn into these chambers, spatially fixed, and their interactions are monitored over extended periods—up to 14 hours—using time-lapse microscopy. The design enables researchers to create a wide variety of experimental conditions: cancer cells alone, immune cells alone, or various ratios of immune cells to cancer cells.
"With CellTrap, we can not only measure whether immune cells kill cancer cells, but also track when and under what conditions this occurs. This matters, because immune responses can vary so much from one cell to the next," said Ghulam Destgeer, Professor of Control and Manipulation of Microscale Living Objects at the TUM School of Computation, Information and Technology. "And we deliberately kept the platform simple and affordable: it runs on a standard fluorescence microscope of the kind most labs already have, with no specialised equipment."
Key Findings in Glioblastoma (搜索)
Initial experiments using a glioblastoma (搜索) cell line—a type of brain tumor—yielded important insights. The data confirmed that when multiple immune cells encounter a single cancer cell, the cancer cell is attacked more frequently and more intensely. More notably, the platform revealed that early activation signals in immune cells often indicate that a cell-damaging effect will occur later. This marks the first time researchers have been able to directly observe how early reactions relate to later outcomes within the same cell-cell interaction.
Beyond the glioblastoma (搜索) line, the team validated CellTrap with two additional cancer cell lines: a chronic myeloid leukemia (搜索) and an adenocarcinoma (搜索), demonstrating the platform's versatility across different tumor types.
Broader Implications for Immunotherapy Research
"The more we learn about what actually happens between individual cells, the better we can compare treatment strategies and develop new ones," Destgeer added. He emphasized that while the team focused on immune and cancer cells, the platform is not limited to these cell types—almost any combination of cells can be loaded and observed in the chip.
By enabling the direct correlation of early cellular activation events with later functional outcomes, CellTrap could inform the development and optimization of immunotherapeutic approaches, offering researchers a powerful tool to dissect the heterogeneity of immune responses at single-cell resolution.